News

Pulmonary Hypertension: One Family’s Long, Hard Journey

Erica Huntzinger, today a pulmonary hypertension (PH) activist and advocate, remembers her mother, Susan, beginning to experience PH symptoms in her mid-30s, but going improperly undiagnosed for more than a quarter century. During this period, Susan suffered two respiratory failures, a heart attack, and as many as five emergency room visits a year…

Oxygen Therapy Seen to Harm Lungs of Newborns with Pulmonary Hypertension

Oxygen therapy given newborns with persistent pulmonary hypertension likely works to cement the molecular changes that led to the condition in the first place, further worsening, rather than treating, the illness. The study, “Hypoxia and hyperoxia potentiate PAF receptor-mediated effects in newborn ovine pulmonary arterial smooth muscle cells: significance in oxygen…

Actelion to Start a Phase 3 Trial Evaluating Opsumit as Treatment for Children with PAH

Actelion will soon start a Phase 3 clinical trial to assess the effectiveness of Opsumit (macitentan) in delaying the progression of pulmonary arterial hypertension (PAH) in children and adolescents. The long-term trial, called TOMORROW (pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide), will be conducted in more than 20 countries and may lead to the first approved…

Likelihood of PAH in Scleroderma Patients May Be Evident in Specific Autoantibodies

Researchers in Italy developed a clear way of exploring differences in autoantibodies to predict which scleroderma patients are likely to develop pulmonary arterial hypertension (PAH), improving their chances of getting appropriate treatment before changes in their lung blood vessels take place. The study, “Subspecificities of anticentromeric protein A antibodies identify…